New hope for rheumatoid arthritis sufferers: experimental drug GenSci120 enters phase 2 trial
NCT ID NCT07423533
First seen Feb 20, 2026 · Last updated Jun 09, 2026 · Updated 18 times
Summary
This study tests a new injection called GenSci120 for people with moderate to severe rheumatoid arthritis (RA) who did not get enough relief from standard medications. About 450 adults aged 18-70 will receive either GenSci120, a placebo, or an active comparator over 14 weeks, with follow-up. The goal is to see if GenSci120 reduces joint pain and swelling better than placebo.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RHEUMATOID ARTHRITIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Peking University People's Hospital
RECRUITINGBeijing, Beijing Municipality, 100044, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.